Loading...
Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer
Garassino, M. C. Paz-Ares, L. Hui, R. Spira, A. Planchard, D. Özgüroğlu, M. Daniel, D. Vicente, D. Murakami, S.
Garassino, M. C.
Paz-Ares, L.
Hui, R.
Spira, A.
Planchard, D.
Özgüroğlu, M.
Daniel, D.
Vicente, D.
Murakami, S.
Citations
Altmetric:
Abstract
Aim: We retrospectively investigated the impact of tumor PD-L1 expression and prior chemoradiotherapy (CRT)-related variables on patient-reported outcomes (PROs) from PACIFIC. Patients & methods: PACIFIC was a Phase III study of durvalumab versus placebo after CRT in patients with unresectable, stage III non-small-cell lung cancer. If available, pre-CRT tumor tissue was tested for PD-L1 tumor-cell expression, scored at prespecified (25%) and post-hoc (1%) cut-offs. PROs were assessed using EORTC QLQ C30/-LC13. Results: Similar to the intent-to-treat (ITT) population, most PROs remained stable over time across PD-L1 and CRT subgroups, with few clinically relevant differences between treatment arms. Time to deterioration was generally similar to the ITT population. Conclusion: Neither PD-L1 expression nor prior CRT-related variables influenced PROs with durvalumab therapy. Clinical trial registration: NCT02125461 (ClinicalTrials.gov).
Description
Date
2021
Publisher
Collections
Files
Loading...
From UNPAYWALL
Adobe PDF, 2.05 MB
Keywords
Type
Article
Citation
Garassino MC, Paz-Ares L, Hui R, Faivre-Finn C, Spira A, Planchard D, et al. Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer. Future Oncol. 2021;17(10):1165-84.